Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immulina in Long COVID (PASC)
NCT05524532Phase 3Completed
- Sponsor
- University of Mississippi Medical Center
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in post acute COVID-19 syndrome comparing Immulina TM 800 mg/day with Placebo (2 arms). Primary endpoints: Plasma Interleukin 6 at 12 weeks, Plasma C-Reactive Protein at 12 weeks and 1 more. Started Jul 2023; status: completed.
02
Drugs
pidotimod
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT05524532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524532.